ANABIOTICASubmit a source
Peptides

Tesamorelin

An approved growth-hormone-releasing peptide that reduces visceral fat in HIV-associated lipodystrophy but is not a general weight-loss or anti-aging treatment.

Strong
Evidence rating
Evidence review

What the evidence says

Tesamorelin is a growth-hormone-releasing factor analogue approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its label explicitly says it is not indicated for weight loss, is weight neutral, and lacks established long-term cardiovascular safety.[1]

In a 412-person 26-week randomized trial, visceral adipose tissue fell 15.2% with tesamorelin versus increasing 5.0% with placebo, while triglycerides improved and IGF-1 rose. A separate 404-person program found approximately 18% visceral-fat reduction with continued treatment.[2][3]

Participants switched from tesamorelin to placebo regained visceral fat, supporting ongoing disease treatment rather than a short cosmetic cycle. Small HIV studies also report less liver fat, but the significance for liver or cardiovascular events remains uncertain.[3][4]

Healthy-aging claims are not established. A 152-person 20-week growth-hormone-releasing-hormone trial reported a favorable composite cognitive effect, whereas a 2026 pilot in 22 people found no direct significant cognitive change. Neither study demonstrates dementia prevention or longer healthspan.[5][6]

Label risks include elevated IGF-1, glucose intolerance or diabetes, edema, joint pain, carpal tunnel syndrome, hypersensitivity, injection-site reactions, and malignancy precautions. Tesamorelin is also prohibited at all times under WADA rules.[1][7]

Potential benefits

  • Reduces excess visceral abdominal fat in adults with HIV-associated lipodystrophy.[2][3]
  • Can reduce liver fat in selected patients with HIV, although clinical outcome benefit is unproven.[4]

Side effects and cautions

  • Elevated IGF-1, glucose intolerance, fluid retention, joint symptoms, and injection-site reactions require monitoring.[1]
  • It is not an approved general fat-loss, cognition, bodybuilding, or anti-aging medicine, and it carries anti-doping consequences.[1][7]
How we scored it

Evidence breakdown

Large phase 3 trials support one narrow indication; evidence for cognition, physique enhancement, or healthy aging is small and conflicting.

Clinical relevanceHigh

Pivotal trials measure visceral-fat reduction in the approved patient population.

Study qualityHigh

The approved indication rests on large randomized placebo-controlled trials.

Safety dataHigh

Prescribing information defines monitoring, contraindications, and common adverse effects.

References

Full source list

  1. Egrifta WR (tesamorelin) prescribing information

    DailyMed, U.S. National Library of Medicine · 2025

  2. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV

    The New England Journal of Medicine · 2007

  3. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

    Journal of Acquired Immune Deficiency Syndromes · 2010

  4. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    The Lancet HIV · 2019

  5. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

    Archives of Neurology · 2012

  6. The effect of growth hormone-releasing hormone on cognition and brain connectivity in healthy older adults and those with mild cognitive impairment

    eNeurologicalSci · 2026

  7. 2026 List of Prohibited Substances and Methods

    World Anti-Doping Agency · 2026